Germline Pharmacogenetics of Cancer Treatment

Guest Editor:

Dr. Daniel L. Hertz
Department of Clinical Pharmacy, University of Michigan College of Pharmacy, 428 Church St. Ann Arbor, MI 48109-1065

Deadline for manuscript submissions:
closed (28 February 2021)

Message from the Guest Editor

Dear Colleagues,

The patient's inherited germline genome can be important for determining how they process (pharmacokinetics) or respond to (pharmacodynamics) cancer treatment. This Special Issue will describe the current status of germline pharmacogenetics in oncology and report novel findings in this field. Original research articles can describe the discovery, replication, or implementation of germline cancer pharmacogenetics associations, including associations with drug pharmacokinetics, treatment efficacy or toxicity. Review articles describing the current state of knowledge of pharmacogenetic associations in oncology or their clinical implementation are also welcome.

Special Issue

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us